ILC Therapeutics

#Antivirals #Dermatology #Fundraising #ILC Therapeutics #Infectious diseases

ILC Therapeutics raises £2.5m to develop hybrid interferons

Glasgow, UK-based ILC Therapeutics has successfully completed a fundraise of £2.5 ($3.2) million. The company develops hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications. The money will support the continued pre-clinical development of the company’s two lead assets, Alfacyte and Dermacyte, as they move… Read More

#Business & Investment #News